Your browser doesn't support javascript.
loading
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
Loberg, Matthew A; Bell, Rebecca K; Goodwin, Leslie O; Eudy, Elizabeth; Miles, Linde A; SanMiguel, Jennifer M; Young, Kira; Bergstrom, David E; Levine, Ross L; Schneider, Rebekka K; Trowbridge, Jennifer J.
Afiliação
  • Loberg MA; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Bell RK; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Goodwin LO; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Eudy E; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Miles LA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • SanMiguel JM; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Young K; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Bergstrom DE; The Jackson Laboratory, Bar Harbor, ME, USA.
  • Levine RL; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schneider RK; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Trowbridge JJ; The Jackson Laboratory, Bar Harbor, ME, USA. Jennifer.Trowbridge@jax.org.
Leukemia ; 33(7): 1635-1649, 2019 07.
Article em En | MEDLINE | ID: mdl-30692594
ABSTRACT
Clonal hematopoiesis (CH) is a common aging-associated condition with increased risk of hematologic malignancy. Knowledge of the mechanisms driving evolution from CH to overt malignancy has been hampered by a lack of in vivo models that orthogonally activate mutant alleles. Here, we develop independently regulatable mutations in DNA methyltransferase 3A (Dnmt3a) and nucleophosmin 1 (Npm1), observed in human CH and AML, respectively. We find Dnmt3a mutation expands hematopoietic stem and multipotent progenitor cells (HSC/MPPs), modeling CH. Induction of mutant Npm1 after development of Dnmt3a-mutant CH causes progression to myeloproliferative disorder (MPD), and more aggressive MPD is observed with longer latency between mutations. MPDs uniformly progress to acute myeloid leukemia (AML) following transplant, accompanied by a decrease in HSC/MPPs and an increase in myeloid-restricted progenitors, the latter of which propagate AML in tertiary recipient mice. At a molecular level, progression of CH to MPD is accompanied by selection for mutations activating Ras/Raf/MAPK signaling. Progression to AML is characterized by additional oncogenic signaling mutations (Ptpn11, Pik3r1, Flt3) and/or mutations in epigenetic regulators (Hdac1, Idh1, Arid1a). Together, our study demonstrates that Npm1 mutation drives evolution of Dnmt3a-mutant CH to AML and rate of disease progression is accelerated with longer latency of CH.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Leucemia Mieloide Aguda / Transformação Celular Neoplásica / Modelos Animais de Doenças / DNA (Citosina-5-)-Metiltransferases / Evolução Clonal / Mutação / Transtornos Mieloproliferativos Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Leucemia Mieloide Aguda / Transformação Celular Neoplásica / Modelos Animais de Doenças / DNA (Citosina-5-)-Metiltransferases / Evolução Clonal / Mutação / Transtornos Mieloproliferativos Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos